This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Conditions

• Atopic Dermatitis

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions. The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.

Key Dates

Start date

Nov 17, 2025

Status verified

May 2026

Primary completion

Jan 30, 2034

Completion

Jan 30, 2034

Study Design

Enrollment

1,000 participants (estimated)

Arms

• Arm: Atopic Dermatitis
  This study plans to collect information on adolescent and adult patients with atopic dermatitis who initiate or switch any systemic treatment (eg, biologics, oral Janus kinase \[JAK\] inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil) for AD according to the country-specific prescribing information. During the study, investigators will prescribe medical products for treatment of AD per standard of care (SoC) and per medical judgment.

Primary Outcome Measure

Number of Participants Utilizing Atopic Dermatitis (AD) Treatment [ Time Frame: Baseline to up to 60 months ]

Central Contacts

• Trial Transparency email recommended (Toll free for US & Canada)
  800-633-1610
  [email protected]

Locations (43)

Find similar trials in Birmingham, AL

Related Studies

• Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
  PHASE4 · Recruiting · Northwestern University · Chicago, Illinois
• Ethnic Differences in Mechanisms of Action of Dupilumab
  PHASE4 · Recruiting · University of Michigan · Ann Arbor, Michigan
• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
  PHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama